468 related articles for article (PubMed ID: 32057288)
1. Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.
Molina ER; Chim LK; Barrios S; Ludwig JA; Mikos AG
Tissue Eng Part B Rev; 2020 Jun; 26(3):249-271. PubMed ID: 32057288
[TBL] [Abstract][Full Text] [Related]
2. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
3. 3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization.
Molina ER; Chim LK; Salazar MC; Koons GL; Menegaz BA; Ruiz-Velasco A; Lamhamedi-Cherradi SE; Vetter AM; Satish T; Cuglievan B; Smoak MM; Scott DW; Ludwig JA; Mikos AG
ACS Biomater Sci Eng; 2020 Jan; 6(1):539-552. PubMed ID: 33463239
[TBL] [Abstract][Full Text] [Related]
4. The Tumor Microenvironment of Pediatric Sarcoma: Mesenchymal Mechanisms Regulating Cell Migration and Metastasis.
Ehnman M; Chaabane W; Haglund F; Tsagkozis P
Curr Oncol Rep; 2019 Aug; 21(10):90. PubMed ID: 31418125
[TBL] [Abstract][Full Text] [Related]
5. Tissue-Engineered Bone Tumor as a Reproducible Human in Vitro Model for Studies of Anticancer Drugs.
Sakolish C; House JS; Chramiec A; Liu Y; Chen Z; Halligan SP; Vunjak-Novakovic G; Rusyn I
Toxicol Sci; 2020 Jan; 173(1):65-76. PubMed ID: 31626302
[TBL] [Abstract][Full Text] [Related]
6. IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells.
Lissat A; Joerschke M; Shinde DA; Braunschweig T; Meier A; Makowska A; Bortnick R; Henneke P; Herget G; Gorr TA; Kontny U
BMC Cancer; 2015 Jul; 15():552. PubMed ID: 26215971
[TBL] [Abstract][Full Text] [Related]
7. 3D tissue-engineered model of Ewing's sarcoma.
Lamhamedi-Cherradi SE; Santoro M; Ramammoorthy V; Menegaz BA; Bartholomeusz G; Iles LR; Amin HM; Livingston JA; Mikos AG; Ludwig JA
Adv Drug Deliv Rev; 2014 Dec; 79-80():155-71. PubMed ID: 25109853
[TBL] [Abstract][Full Text] [Related]
8. Pericytes in sarcomas of bone.
Chang L; Nguyen V; Nguyen A; Scott MA; James AW
Med Oncol; 2015 Jul; 32(7):202. PubMed ID: 26076804
[TBL] [Abstract][Full Text] [Related]
9. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.
Santoro M; Menegaz BA; Lamhamedi-Cherradi SE; Molina ER; Wu D; Priebe W; Ludwig JA; Mikos AG
Tissue Eng Part A; 2017 Jan; 23(1-2):80-89. PubMed ID: 27923328
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
11. Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research.
Bozorgi A; Sabouri L
Cancer Treat Res Commun; 2021; 27():100324. PubMed ID: 33517237
[TBL] [Abstract][Full Text] [Related]
12. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds.
Fong EL; Lamhamedi-Cherradi SE; Burdett E; Ramamoorthy V; Lazar AJ; Kasper FK; Farach-Carson MC; Vishwamitra D; Demicco EG; Menegaz BA; Amin HM; Mikos AG; Ludwig JA
Proc Natl Acad Sci U S A; 2013 Apr; 110(16):6500-5. PubMed ID: 23576741
[TBL] [Abstract][Full Text] [Related]
13. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
14. Bioengineered human tumor within a bone niche.
Villasante A; Marturano-Kruik A; Vunjak-Novakovic G
Biomaterials; 2014 Jul; 35(22):5785-94. PubMed ID: 24746967
[TBL] [Abstract][Full Text] [Related]
15. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes.
Bajpai J; Khanna N; Vora T; Gulia A; Laskar S; Puri A; Sanduptla B; Chinnaswamy G; Nayak P; Juvekar SL; Janu A; Desai S; Ghosh J; Purandare N; Ramadwar M; Rangarajan V; Rekhi B
Indian J Cancer; 2018; 55(1):37-44. PubMed ID: 30147091
[TBL] [Abstract][Full Text] [Related]
16. Biomechanical Aspects in Bone Tumor Engineering.
Menshikh K; Banicevic I; Obradovic B; Rimondini L
Tissue Eng Part B Rev; 2024 Apr; 30(2):217-229. PubMed ID: 37830183
[TBL] [Abstract][Full Text] [Related]
17. Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.
Vormoor B; Knizia HK; Batey MA; Almeida GS; Wilson I; Dildey P; Sharma A; Blair H; Hide IG; Heidenreich O; Vormoor J; Maxwell RJ; Bacon CM
PLoS One; 2014; 9(1):e85128. PubMed ID: 24409320
[TBL] [Abstract][Full Text] [Related]
18. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
19. Relevance of 3d culture systems to study osteosarcoma environment.
De Luca A; Raimondi L; Salamanna F; Carina V; Costa V; Bellavia D; Alessandro R; Fini M; Giavaresi G
J Exp Clin Cancer Res; 2018 Jan; 37(1):2. PubMed ID: 29304852
[TBL] [Abstract][Full Text] [Related]
20. Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation?
Malik AT; Alexander JH; Mayerson JL; Khan SN; Scharschmidt TJ
Clin Orthop Relat Res; 2020 Oct; 478(10):2284-2295. PubMed ID: 32667758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
